BRUIN MCL-321

A Phase 3 Open-Label, Randomized Study of LOXO-305
versus Investigator Choice of BTK Inhibitor in Patients with
Previously Treated BTK Inhibitor Naïve Mantle Cell
Lymphoma (BRUIN MCL-321)

Menu